针对急性呼吸困扰综合征的基于细胞的疗法:我们现在在哪里?
Gerard F Curley1, Cecilia M O'Kane2, Daniel F McAuley2,3
1Department of Anaesthesia, Royal College of Surgeons in Ireland, Dublin, Ireland.
American journal of respiratory and critical care medicine
|February 7, 2024
概括
介酶体 stromal 细胞 (MSCs) 通过减少炎症和促进修复,对急性呼吸困扰综合征 (ARDS) 有希望. 需要进一步的研究来克服挑战,并充分评估它们在ARDS患者中的治疗潜力.
科学领域:
- 再生医学是一种再生医学.
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
背景情况:
- 中介质层细胞 (MSCs) 正在研究急性呼吸困扰综合征 (ARDS) 治疗.
- MSCs调节炎症,减少肺透性,并促进组织修复.
- 临床研究表明MSC是安全的,并具有潜在的益处,一些监管部门批准了特定用途.
研究的目的:
- 重新评估基于MSC的ARDS治疗方法的治疗潜力.
- 结合COVID-19和经典ARDS近期细胞疗法试验的见解.
- 识别对ARDS的MSC疗法翻译的知识差距和挑战.
主要方法:
- 对COVID-19和ARDS近期临床试验的审查.
- 对移植与宿主疾病研究的分析,获得许可的MSC指示.
- 在ARDS的MSC治疗中识别未知因素和挑战.
主要成果:
- 多重体细胞显示出与ARDS相关的多方面的治疗机制.
- 临床数据表明安全性和潜在的疗效,但需要更多的研究.
- 移植与宿主疾病为MSC治疗的调节和应用提供了一个模型.
结论:
- 基于MSC的疗法对ARDS治疗具有重大前景.
- 必须解决关键的未知和翻译挑战.
- 提出了一种结构化的方法,以促进对ARDS的MSCs的临床评估.
相关概念视频
01:29Acute Respiratory Failure-V
140
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
140
01:21Acute Respiratory Failure-I
209
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
209
01:30Acute Respiratory Failure-III
187
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
187
01:23Acute Respiratory Failure-IV
158
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
158
01:21Acute Respiratory Failure-II
236
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
236